Skip to main content
SpringerLink
Log in

Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Intravenous dalbavancin (Dalvance®, Xydalba®), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin and its clinical efficacy and tolerability as a single-dose regimen in the treatment of adult patients with ABSSSI. Single-dose dalbavancin is an effective and generally well tolerated treatment option for adults with ABSSSI, with noninferior efficacy to the two-dose dalbavancin regimen with regard to early clinical response (at 48–72 h) and low rates of adverse events. Clinical success rates at days 14 and 28 also did not significantly differ between the single- and two-dose dalbavancin regimens; neither did clinical success rates at day 14 when analysed by baseline pathogen. It has a broad spectrum of activity against common ABSSSI-related pathogens, and a favourable pharmacokinetic profile allowing for the convenience of single-dose administration. Thus, dalbavancin presents a promising alternative to conventional antibacterials for the treatment of ABSSSI in adult patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Juul JJ, Mullins CF, Peppard WJ, et al. New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin. Ther Clin Risk Manag. 2016;12:225–32.

    PubMed  PubMed Central  Google Scholar 

  2. Leuthner KD, Buechler KA, Kogan D, et al. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag. 2016;12:931–40.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Van Bambeke F. Lipoglycopeptide antibacterial agents in Gram-positive infections: a comparative review. Drugs. 2015;75(18):2073–95.

    Article  PubMed  Google Scholar 

  4. Durata Therapeutics US Ltd. Dalvance® (dalbavancin for injection, for intravenous use): US prescribing information. 2016. http://www.allergan.com. Accessed 11 Nov 2016.

  5. European Medicines Agency. Xydalba® (dalbavancin powder for concentrate for solution for infusion): EU summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 11 Nov 2016.

  6. Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–79.

    Article  PubMed  Google Scholar 

  7. Scott LJ. Dalbavancin: a review in acute bacterial skin and skin structure infections. Drugs. 2015;75(11):1281–91.

    Article  CAS  PubMed  Google Scholar 

  8. Anderson VR, Keating GM. Dalbavancin. Drugs. 2008;68(5):639–48.

    Article  CAS  PubMed  Google Scholar 

  9. Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859–86.

    Article  CAS  PubMed  Google Scholar 

  10. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016. 2016. http://www.eucast.org/clinical_breakpoints/. Accessed 11 Nov 2016.

  11. Lin G, Credito K, Ednie LM, et al. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother. 2005;49(2):770–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lopez S, Hackbarth C, Romano G, et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother. 2005;55(Suppl 2):ii21–4.

  13. Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48(3):940–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Streit JM, Fritsche TR, Sader HS, et al. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis. 2004;48(2):137–43.

    Article  CAS  PubMed  Google Scholar 

  15. Biedenbach DJ, Bell JM, Sader HS, et al. Activities of dalbavancin against a worldwide collection of 81,673 Gram-positive bacterial isolates. Antimicrob Agents Chemother. 2009;53(3):1260–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Jones RN, Farrell DJ, Flamm RK, et al. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagn Microbiol Infect Dis. 2015;82(1):73–7.

    Article  CAS  PubMed  Google Scholar 

  17. Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis. 2013;75(3):304–7.

    Article  CAS  PubMed  Google Scholar 

  18. Jones RN, Flamm RK, Sader HS. Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn Microbiol Infect Dis. 2013;76(1):122–3.

    Article  CAS  PubMed  Google Scholar 

  19. Karlowsky JA, Adam HJ, Poutanen SM, et al. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007–2009 study. Diagn Microbiol Infect Dis. 2011;69(3):342–7.

    Article  CAS  PubMed  Google Scholar 

  20. Huband MD, Castanheira M, Farrell DJ, et al. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011–2013). Int J Antimicrob Agents. 2016;47(6):495–9.

    Article  CAS  PubMed  Google Scholar 

  21. Mendes RE, Castanheira M, Farrell DJ, et al. Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011–13). J Antimicrob Chemother. 2016;71(1):276–8.

    Article  CAS  PubMed  Google Scholar 

  22. Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545–51.

    Article  PubMed  Google Scholar 

  23. Dunne M, Boucher H, Wilcox MH, et al. Microbiologic analysis of target pathogens identified in the dalbavancin DISCOVER program [abstract no. 1338]. In: Infectious Diseases Week. 2013.

  24. Klinker KP, Borgert SJ. Beyond vancomycin: the tail of the lipoglycopeptides. Clin Ther. 2015;37(12):2619–36.

    Article  CAS  PubMed  Google Scholar 

  25. Johnson DM, Fritsche TR, Sader HS, et al. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int J Antimicrob Agents. 2006;27(6):557–60.

    Article  CAS  PubMed  Google Scholar 

  26. Koeth LM, DiFranco-Fisher JM, Dunne M, et al. Dalbavancin and azithromycin synergy/antagonism study by checkerboard MIC [abstract no. D-877]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.

  27. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007;51(5):1633–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicob Chemother. 2006;58(4):802–5.

    Article  CAS  Google Scholar 

  29. Bhavnani SM, Hammel JP, Rubino CM, et al. Pharmacokinetic–pharmacodynamic (PK–PD) analyses for the efficacy of dalbavancin (DAL) using phase 3 data from patients with acute bacterial skin and skin structure infections (ABSSSI) [abstract no. A-1186]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.

  30. Dunne MW, Zhou M, Darpo B. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents. 2015;45(4):393–8.

    Article  CAS  PubMed  Google Scholar 

  31. Nicolau DP, Sun HK, Seltzer E, et al. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicob Chemother. 2007;60(3):681–4.

    Article  CAS  Google Scholar 

  32. Scoble PJ, Owens RC Jr, Puttagunta S. Pharmacokinetics, safety, and tolerability of a single 500-mg or 1000-mg intravenous dose of dalbavancin in healthy Japanese subjects. Clin Drug Investig. 2015;35(12):785–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Data on file, Allergan, 2015.

  34. Tran MC, Naumovski S, Goldstein EJ. The times they are a-changin’: new antibacterials for skin and skin structure infections. Am J Clin Dermatol. 2015;16(3):137–46.

    Article  PubMed  Google Scholar 

  35. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10–52.

    Article  PubMed  Google Scholar 

  36. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.

    Article  PubMed  Google Scholar 

  37. The Medicines Company. Orbactiv® (oritavancin for injection, for intravenous use): US prescribing information. 2016. http://www.themedicinescompany.com. Accessed 29 Aug 2016.

  38. European Medicines Agency. Orbactiv® (oritavancin 400 mg powder for concentrate for solution for infusion): EU summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 29 Aug 2016.

  39. European Medicines Agency. EMA assessment report for Xydalba® (dalbavancin powder for concentrate for solution for infusion). EMA/39820/2015. 2015. http://www.ema.europa.eu. Accessed 2 Nov 2016.

  40. Syed YY, Scott LJ. Oritavancin: a review in acute bacterial skin and skin structure infections. Drugs. 2015;75(16):1891–902.

    Article  CAS  PubMed  Google Scholar 

  41. Everson-Stewart S, Emerson SS. Bio-creep in non-inferiority clinical trials. Stat Med. 2010;29(27):2769–80.

    Article  PubMed  Google Scholar 

  42. Pollack CV Jr, Amin A, Ford WT Jr, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48(4):508–19.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

During the peer review process, the manufacturer of dalbavancin was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Karly P. Garnock-Jones

Authors
  1. Karly P. Garnock-Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karly P. Garnock-Jones.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Karly P. Garnock-Jones is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

The manuscript was reviewed by: H. Bhally, Department of Medicine and Infectious Diseases, Waitemata District Health Board, Auckland, New Zealand; J. Gallagher, Department of Pharmacy Practice, Temple University, Philadelphia, PA, USA; I.K. Minichmayr, Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany; G. Poulakou, 4th Department of Internal Medicine, Athens Medical School, Attikon University General Hospital, Athens, Greece; G. Siakalis, Department of Infectious Diseases, Attikon University General Hospital, Athens, Greece; F. Van Bambeke, Unité de Pharmacologie Cellulaire et Moléculaire, Universite Catholique de Louvain, Brussels, Belgium; S. Veraldi, Department of Pathophysiology, University of Milan, IRCCS Foundation, Ospedale Maggiore Policlinico, Milan, Italy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garnock-Jones, K.P. Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections. Drugs 77, 75–83 (2017). https://doi.org/10.1007/s40265-016-0666-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-016-0666-0

Keywords

Search

Navigation